Physician profile
Thomas James Bell
NPI 1508898727
$3,351.96
in general payments reported to CMS, 2019-2025
33 companies · $69.73 in 2025
The $69.73 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $148 · 2021: $1,221 · 2022: $874 · 2023: $45.50 · 2025: $69.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $115.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $543.26 | 2019-2022 | |
| Novo Nordisk INC | $455.23 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.70 | 2019-2022 | |
| Abbvie INC. | $248.20 | 2020-2022 | |
| Pfizer INC. | $206.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.31 | 2019-2022 | |
| Astellas Pharma US INC | $157.68 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $154.03 | 2019-2022 | |
| Amarin Pharma, INC. | $114.29 | 2019-2021 | |
| Lilly USA, LLC | $108.28 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $95.67 | 2021-2022 | |
| Amgen INC. | $88.88 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $69.73 | 2025 | Jynarque |
| Glaxosmithkline, LLC. | $67.00 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $55.25 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.94 | 2021-2022 | |
| Esperion Therapeutics, INC. | $41.93 | 2021 | |
| Merck Sharp & Dohme LLC | $38.17 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.68 | 2022 | |
| Mylan Specialty L.P. | $32.86 | 2019-2022 | |
| Abbott Laboratories | $30.92 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.51 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.86 | 2019 | |
| Edwards Lifesciences Corporation | $19.88 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.30 | 2022 | |
| Eagle Pharmaceuticals, INC. | $16.12 | 2023 | |
| Boston Scientific Corporation | $16.10 | 2023 | Rezum Generator |
| Idorsia Pharmaceuticals US INC | $14.50 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.30 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.75 | 2019 | |
| Teleflex LLC | $13.28 | 2023 | Arrow |
| Janssen Pharmaceuticals, INC | $11.46 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.